Acadia Pharmaceuticals | ACAD - Loan Capital


Acadia Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in March of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 1.12B 957.23M Dec/2025
Eisai JPY 134.77B 12M Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
J&J USD 37.53B 1.91B Mar/2026
Moderna USD 610M 584M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 57.41B 93M Sep/2025
Prothena USD 0 0 Dec/2024
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025